Dr. Nancy Reid
Coronavirus disease 2019 (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused global devastation since being initially reported in the Hubei Province of Wuhan, China in December 2019. Early determination of disease severity may help guide management and improve patient outcomes. However, risk stratification and early prognosis still remains challenging. Laboratory markers such as C-reactive protein (CRP), interleukin-6 (IL-6), and D-dimer have been proposed as useful serological indicators to assess prognosis and outcomes in COVID-19 patients. Nevertheless, further research is still needed to establish a strong correlation between these laboratory markers and the clinical progression of COVID-19.
"Laboratory Markers in Assessing Disease Severity of COVID-19,"
Lynchburg Journal of Medical Science: Vol. 3
, Article 73.
Available at: https://digitalshowcase.lynchburg.edu/dmscjournal/vol3/iss3/73
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.